Companies

Genentech Launches Direct-to-Consumer Program, Cuts Flu Vaccine Price by Nearly 70 Percent

The new program follows similar rollouts by drugmakers seeking to put prescription drugs in the hands of American patients at lower costs.
Genentech Launches Direct-to-Consumer Program, Cuts Flu Vaccine Price by Nearly 70 Percent
The Genentech logo displayed at the company's headquarters in San Francisco in a file photo. Justin Sullivan/Getty Images
|Updated:
0:00

Roche Group’s Genentech has joined the growing ranks of pharmaceutical companies selling prescription drugs directly to patients by making its Xofluza antiviral flu medicine available through online pharmacies.

Genentech’s Direct-to-Patient (DTP) program allows patients to order the single-dose vaccine from Alto Pharmacy, Amazon Pharmacy, and Mark Cuban’s Cost Plus Drugs, San Francisco-based Genentech said on Oct. 16. Patients can order the vaccine for $50, a 70-percent reduction from its list price, Genentech said.
Rob Sabo
Rob Sabo
Author
Rob Sabo has worked as a business journalist for nearly two decades and covers a broad range of business topics for The Epoch Times.